Skip to main content
LIFECOME BIOCHEMISTRY CO., LTD. logo

LIFECOME BIOCHEMISTRY CO., LTD. — Investor Relations & Filings

Ticker · 002868 ISIN · CNE100002QH2 LEI · 65560089EP03NANEN790 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,742 across all filing types
Latest filing 2025-12-23 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002868

About LIFECOME BIOCHEMISTRY CO., LTD.

https://www.pclifecome.com

Lifecome Biochemistry Co., Ltd. focuses on the research, development, and large-scale production of fermentation-based veterinary pharmaceuticals and feed additives. The company’s core product portfolio includes Bacitracin Zinc, Bacitracin Methylene Disalicylate (BMD), and Colistin Sulfate, available in both active pharmaceutical ingredient (API) and premix forms. These biochemical products are primarily utilized in the livestock and poultry sectors to manage enteric health and improve feed efficiency. The organization operates advanced fermentation and purification facilities, maintaining compliance with international Good Manufacturing Practices (GMP) and various global regulatory standards. By leveraging specialized biotechnological processes, the company provides high-purity solutions aimed at enhancing animal nutrition and disease prevention across international markets.

Recent filings

Filing Released Lang Actions
关于全资子公司完成工商注册登记的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the completion of business registration for a wholly-owned subsidiary. It includes details about the subsidiary's name, registration number, legal representative, capital, address, and business scope. The document is short (1066 characters) and serves as a formal notice of a corporate event rather than a financial report or detailed filing. There is no financial data, no mention of annual or quarterly results, no audit information, no voting results, or other report types. It is an announcement about a corporate structural event (subsidiary registration). This type of announcement fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-12-23 Chinese
关于控股股东部分股票质押的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the pledge of shares by the company's controlling shareholder. It details the number of shares pledged, the percentage of total shares, and the purpose of the pledge. It explicitly states that the pledge is related to securities investment and does not affect company control or operations. There are no financial statements, earnings data, or management discussion of results. The document is a regulatory disclosure about a shareholder's stock pledge, which fits the category of Capital/Financing Update (CAP) as it relates to financing activities involving the company's capital structure.
2025-12-22 Chinese
第五届董事会第三十次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is titled as a resolution announcement from the company's fifth board of directors' 30th (extraordinary) meeting. It details the meeting date, attendance, and resolutions passed, including approval of a land acquisition contract and scheduling of an extraordinary shareholders' meeting. It includes voting results and references to related announcements. The content focuses on board meeting decisions and governance matters rather than financial results or reports. The document length is short (1102 characters), and it is a formal announcement of board resolutions. Therefore, it fits the category of Board/Management Information (MANG).
2025-12-19 Chinese
2025年第五次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2025 fifth extraordinary general meeting (临时股东会) of the company 绿康生化股份有限公司. It includes voting results on various proposals such as the reappointment of the audit firm, amendments to board meeting rules, election of independent and non-independent directors, financing credit limits, and guarantee limits for subsidiaries. The document also confirms the legality and validity of the meeting and voting process, supported by a legal opinion from a law firm. The content is focused on the official results of shareholder votes at a general meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3228 characters, which is consistent with a detailed voting results announcement rather than a full report or presentation. Therefore, the correct classification is DVA with high confidence.
2025-12-19 Chinese
第五届董事会第三十一次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at a specific board meeting, including the election of a new chairman and legal representative. It details the meeting attendance, voting results, and references compliance with company law and internal rules. There is no financial data, audit information, or report content. The focus is on board/management changes, specifically the election of a new chairman and legal representative. Therefore, this fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear content and context.
2025-12-19 Chinese
上海澄明则正律师事务所关于绿康生化股份有限公司2025年第五次临时股东会的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and validity of procedures, qualifications, and voting results of a company's 2025 fifth extraordinary shareholders' meeting. It details the convening, attendance, voting procedures, and results of the meeting, including election of directors and approval of financing proposals. The document does not contain financial statements or financial performance data but focuses on legal compliance and validation of the shareholders' meeting process and outcomes. This type of document is a legal proceedings report related to corporate governance and shareholder meetings, rather than a direct announcement of voting results or a management report. Therefore, it fits best under the category of Legal Proceedings Report (LTR).
2025-12-19 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.